2 Hepatitis C treatment Articles

[Guest guest]

FDA Updates Dosing of Pegasys plus Ribavirin for

Hepatitis C Patients with Kidney ImpairmentOn

August 9, 2011, the U.S. Food and Drug Administration

(FDA) approved changes to the product label information

for pegylated interferon alfa-2a (Pegasys) plus the Copegus

brand of ribavirin, reflecting new dose recommendations

for people with impaired kidney function. HIV/HCV and HIV/HBV

CoinfectionTreatment of HIV/HCV Coinfected People with

Compensated Liver CirrhosisHIV positive people with

compensated liver cirrhosis related to chronic hepatitis

C virus (HCV) responded as well to treatment with

pegylated interferon and ribavirin as coinfected

patients without cirrhosis, but they should receive closer

monitoring and may need more intensive management of side

effects.

[Guest guest]

FDA Updates Dosing of Pegasys plus Ribavirin for

Hepatitis C Patients with Kidney ImpairmentOn

August 9, 2011, the U.S. Food and Drug Administration

(FDA) approved changes to the product label information

for pegylated interferon alfa-2a (Pegasys) plus the Copegus

brand of ribavirin, reflecting new dose recommendations

for people with impaired kidney function. HIV/HCV and HIV/HBV

CoinfectionTreatment of HIV/HCV Coinfected People with

Compensated Liver CirrhosisHIV positive people with

compensated liver cirrhosis related to chronic hepatitis

C virus (HCV) responded as well to treatment with

pegylated interferon and ribavirin as coinfected

patients without cirrhosis, but they should receive closer

monitoring and may need more intensive management of side

effects.